MetP Pharma
MetP Pharma AG is an independent pharmaceutical R&D and product development company based in Switzerland, specializing in nose-to-brain drug delivery. The company’s proprietary MetP Technology is a comprehensively patented platform that enables direct, efficient delivery of therapeutics to the brain, bypassing the blood-brain barrier.The brain-targeting capabilities of MetP Technology have been validated by several independent research institutions worldwide and are featured in 67 predominantly peer-reviewed publications. The platform has proven its clinical utility in several preclinical and clinical trials and has demonstrated to be fast, safe, effective, user-friendly, and cost-efficient. MetP is actively advancing its own pipeline of intranasal therapeutics targeting conditions such as concussion, insomnia, ADHD, multiple sclerosis (MS), and hypogonadism. A strong global intellectual property portfolio protects the platform until 2037/2039. Beyond formulation, MetP offers an integrated, end-to-end solution including its proprietary unit-dose applicator and industrial-scale filling technology - providing partners with a fully developed, patent-protected, and ready-to-use drug delivery system.Content by MetP Pharma
| 3 min read
Intranasal nose-to-brain delivery achieves superior brain exposure with low systemic burden, outperforming transporter-based BBB technologies in preclinical studies.
Page 1 of 1 - 1 Total Items
